An anonymous reader quotes a report from New Atlas: Researchers have developed a new, lightweight foam made from carbon nanotubes that, when used as a helmet liner, absorbed the kinetic energy caused by an impact almost 30 times better than liners currently used in US military helmets. The foam could prevent or significantly reduce the likelihood of concussion in military personnel and sportspeople. Among sportspeople and military vets, traumatic brain injury (TBI) is one of the major causes of permanent disability and death. Injury statistics show that the majority of TBIs, of which concussion is a subtype, are associated with oblique impacts, which subject the brain to a combination of linear and rotational kinetic energy forces and cause shearing of the delicate brain tissue.

To improve their effectiveness, helmets worn by military personnel and sportspeople must employ a liner material that limits both. This is where researchers from the University of Wisconsin-Madison come in. Determined to prevent -- or lessen the effect of -- TBIs caused by knocks to the body and head, they've developed a new lightweight foam material for use as a helmet liner. For the current study, Thevamaran built upon his previous research into vertically aligned carbon nanotube (VACNT) foams -- carefully arranged layers of carbon cylinders one atom thick -- and their exceptional shock-absorbing capabilities. Current helmets attempt to reduce rotational motion by allowing a sliding motion between the wearer's head and the helmet during impact. However, the researchers say this movement doesn't dissipate energy in shear and can jam when severely compressed following a blow. Instead, their novel foam doesn't rely on sliding layers.

VACNT foam sidesteps this shortcoming via its unique deformation mechanism. Under compression, the VACNTs undergo collective sequentially progressive buckling, from increased compliance at low shear strain levels to a stiffening response at high strain levels. The formed compression buckles unfold completely, enabling the VACNT foam to accommodate large shear strains before returning to a near initial state when the load is removed. The researchers found that at 25% precompression, the foam exhibited almost 30 times higher energy dissipation in shear -- up to 50% shear strain -- than polyurethane-based elastomeric foams of similar density. The study has been published in the journal Experimental Mechanics.

SpaceX on Thursday launched two rockets into orbit, only three hours apart, bringing its total number of launches to 98 in 2023. Space.com reports: The first SpaceX mission to take to the skies Thursday (Dec. 28) was a Falcon Heavy rocket carrying the U.S. military's secretive X-37B space plane, designed mission USSF-52. That blasted off from NASA's Kennedy Space Center in Florida at 8:07 p.m. EST (0107 GMT on Dec. 29). This marked the second Falcon Heavy flight of 2023. Second up on the launch docket for Thursday, hours later, was a Falcon 9 liftoff carrying 23 SpaceX Starlink units to low Earth orbit from nearby Cape Canaveral Space Force Station. This launch took place at 11:01 p.m. EST (0401 GMT on Dec. 29). This was SpaceX's 98th and final launch of 2023, and the 96th flight for a Falcon 9 rocket this year.

SpaceX's 97th launch overall for this year marked the seventh flight for X-37B, but the first time the space plane hitched a lift atop a Falcon Heavy rocket. The X-37B/Falcon Heavy launch had been scrubbed several times previously due to bad weather and an issue with ground equipment. The launch of 23 Starlink broadband satellites from Space Launch Complex 40 (SLC-40) at Cape Canaveral Space Force Station in Florida that capped off 2023 was also the 96th launch of a Falcon 9 rocket during this year. SpaceX's next launch is targeted for Jan. 2, 2024 and will see a further 21 Starlink satellites lift to orbit to join the over 5,500 internet supplying units currently orbiting Earth.

In 2021, Philips pulled its popular sleep apnea machines and ventilators off the shelves after discovering that an industrial foam built into the devices to reduce noise could release toxic particles and fumes into the masks worn by patients. "But as Philips publicly pledged to send out replacements, supervisors inside the company's headquarters near Pittsburgh were quietly racing to manage a new crisis that threatened the massive recall and posed risks to patients all over again," reports ProPublica. "Tests by independent laboratories retained by Philips had found that a different foam used by the company -- material fitted inside the millions of replacement machines -- was also emitting dangerous chemicals, including formaldehyde, a known carcinogen."

"Though Philips has said the machines are safe, ProPublica and the Pittsburgh Post-Gazette obtained test results and other internal records that reveal for the first time how scientists working for the company grew increasingly alarmed and how infighting broke out as the new threat reached the highest levels of the Pittsburgh operation. The findings also underscore an unchecked pattern of corporate secrecy that began long before Philips decided to use the new foam." From the report: The company had previously failed to disclose complaints about the original foam in its profitable breathing machines, a polyester-based polyurethane material that was found to degrade in heat and humidity. Former patients and others have described hundreds of deaths and thousands of cases of cancer in government reports. After the introduction of the new foam in 2021, this one made of silicone, the company again held back details about the problem from the public even as it sent out replacement machines with the new material to customers around the world.

One of the devices was the DreamStation 2, a newly released continuous positive airway pressure, or CPAP, machine promoted as one of the company's primary replacements. Federal regulators were alerted to the concern more than two years ago but said in a news release at the time that the company was carrying out additional tests on the foam and that patients should keep using their replacements until more details were available. The Food and Drug Administration has not provided new information on the test results since then, and it is still unclear whether the material is safe. That leaves millions of people in the United States alone caught in the middle, including those with sleep apnea, which causes breathing to stop and start through the night and can lead to heart attacks, strokes and sudden death.

The new foam isn't the only problem: An internal investigation at Philips launched in the months after the recall found that water was condensing in the circuitry of the DreamStation 2, creating a new series of safety risks. "Loss of therapy, thermal events, and shock hazards," the investigation concluded. The FDA issued an alert about overheating last month, warning that the devices could produce "fire, smoke, burns, and other signs of overheating" and advising patients to keep the machines away from carpet, fabric and "other flammable materials." Philips has said that customers could continue using the devices if they followed safety instructions. ...

An anonymous reader quotes a report from Bloomberg, written by Naomi Kresge: In the early days of the Covid-19 pandemic, hundreds of scientists from all over the world banded together in an open-source effort to develop an antiviral that would be available for all. They could never have anticipated the many roadblocks they would face along the way, including the Russian invasion of Ukraine, which made refugees out of a group of Kyiv chemists who were doing important work for the project. The group, which called itself Covid Moonshot, hasn't given up on its effort to introduce a more affordable, patent-free treatment for the virus. Their open-source Covid antiviral, now funded by Wellcome, is on track to be ready for human testing within the next year and a half, according to Annette von Delft, a University of Oxford scientist and one of the Moonshot group's leaders. More early discovery work on a range of potential inhibitors for other viruses is also still going on and being funded by a US government grant.

"It's a bit like a proof of concept," von Delft says, for bringing a patent-free experimental drug into the clinic, a model that could be repurposed as a tool to fight neglected tropical diseases or antimicrobial resistance, or prepare for future pandemics. "Can we come up with a strategic model that can help those kinds of compounds with less of a business case along?" Of course, there was definitely a business case for a Covid antiviral, and some of the biggest drugmakers rushed to develop them. In 2022, Pfizer Inc.'s Paxlovid was one of the world's best-selling medicines with $18.9 billion in revenue. Demand has since cratered for the pill, which needs to be given shortly after infection and can't be taken alongside a number of other commonly prescribed medicines. Analysts expect the Paxlovid revenue to plunge just shy of $1 billion this year.

However, there is still a need for a better Covid antiviral, particularly in countries where access to the Pfizer pill is limited, according to von Delft. Covid cases have surged again this holiday season, with the rise of a new variant called JN.1 reminding us that the virus is still changing to evade the immunity we've built up so far. Just before Christmas, UK authorities said about one in every 24 people in England and Scotland had the disease. An accessible antiviral could help people return to work more quickly, and it could also be tested as a potential treatment for long Covid. "We know from experience in viral disease that there will be resistance variants evolving over time," von Delft said. "We'll need more than one."

Andy Maxwell reports via TorrentFreak: As the crew of Artemis 2 prepare to become the first humans to fly to the moon since 1972, the possibilities of space travel are once again igniting imaginations globally. More than 92% of internet users who want to learn more about this historic mission and the program in general are statistically likely to use Google search. Behind the scenes, however, the ability to find relevant content is under attack. Blundering DMCA takedown notices sent by a company calling itself DMCA Piracy Prevention Inc. claim to protect the rights of an OnlyFans/Instagram model working under the name 'Artemis'. Instead, keyword-based systems that fail to discriminate between copyright-infringing content and that referencing the word Artemis in any other context, are flooding towards Google. They contain demands to completely deindex non-infringing, unrelated content, produced by innocent third parties all over the world.

A recent deindexing demand dated December 13, 2022, lists DMCA Piracy Prevention Inc. of Canada as the sender. The name of the content owner is redacted but the notice itself states that the company represents a content creator performing under the name Artemis. The notice demands the removal of 3,617 URLs from Google search. If successful, those URLs would be completely unfindable by more than 92% of the world's population who use that search engine. [...] At least 9 of the first 20 URLs in the notice demand the removal of non-infringing articles and news reports referencing the Artemis space program. None have anything to do with the content the sender claims to protect. [...]

Theories as to who might own and/or operate DMCA Piracy Prevention Inc. aren't hard to find but the company does exist and is registered as a corporate entity in Canada. Registered at the same address is a company with remarkably similar details. BranditScan is a corporate entity operating in exactly the same market offering similar if not identical services. BranditScan has sent DMCA takedown notices to Google under three different notifier accounts.

Following policy adjustments by the U.S. Citizenship and Immigration Services (USCIS) in January, more foreign-born workers in science, technology, engineering, and math (STEM) fields are able to live and work permanently in the United States. "The jump comes after USCIS in January 2022 tweaked its guidance criteria relating to two visa categories available to STEM workers," reports Science Magazine. "One is the O-1A, a temporary visa for 'aliens of extraordinary ability' that often paves the way to a green card. The second, which bestows a green card on those with advanced STEM degrees, governs a subset of an EB-2 (employment-based) visa." From the report: The USCIS data, reported exclusively by ScienceInsider, show that the number of O-1A visas awarded in the first year of the revised guidance jumped by almost 30%, to 4570, and held steady in fiscal year 2023, which ended on 30 September. Similarly, the number of STEM EB-2 visas approved in 2022 after a "national interest" waiver shot up by 55% over 2021, to 70,240, and stayed at that level this year. "I'm seeing more aspiring and early-stage startup founders believe there's a way forward for them," says Silicon Valley immigration attorney Sophie Alcorn. She predicts the policy changes will result in "new technology startups that would not have otherwise been created."

President Joe Biden has long sought to make it easier for foreign-born STEM workers to remain in the country and use their talent to spur the U.S. economy. But under the terms of a 1990 law, only 140,000 employment-based green cards may be issued annually, and no more than 7% of those can go to citizens of any one country. The ceiling is well below the demand. And the country quotas have created decades-long queues for scientists and high-tech entrepreneurs born in India and China. The 2022 guidance doesn't alter those limits on employment-based green cards but clarifies the visa process for foreign-born scientists pending any significant changes to the 1990 law. The O-1A work visa, which can be renewed indefinitely, was designed to accelerate the path to a green card for foreign-born high-tech entrepreneurs.

Although there is no cap on the number of O-1A visas awarded, foreign-born scientists have largely ignored this option because it wasn't clear what metrics USCIS would use to assess their application. The 2022 guidance on O-1As removed that uncertainty by listing eight criteria -- including awards, peer-reviewed publications, and reviewing the work of other scientistsâ"and stipulating that applicants need to satisfy at least three of them. The second visa policy change affects those with advanced STEM degrees seeking the national interest waiver for an EB-2. Under the normal process of obtaining such a visa, the Department of Labor requires employers to first satisfy rules meant to protect U.S. workers from foreign competition, for example, by showing that the company has failed to find a qualified domestic worker and that the job will pay the prevailing wage. That time-consuming exercise can be waived if visa applicants can prove they are doing "exceptional" work of "substantial merit and national importance." But once again, the standard for determining whether the labor-force requirements can be waived was vague, so relatively few STEM workers chose that route. The 2022 USCIS guidance not only specifies criteria, which closely track those for the nonimmigrant, O-1A visa, but also allows scientists to sponsor themselves.

Scientists discovered a way to break apart the membranes of cancer cells by stimulating aminocyanine molecules with near-infrared light. Slashdot reader Baron_Yam shares a report from ScienceAlert: The research team from Rice University, Texas A&M University, and the University of Texas, says the new approach is a marked improvement over another kind of cancer-killing molecular machine previously developed, called Feringa-type motors, which could also break the structures of problematic cells. "It is a whole new generation of molecular machines that we call molecular jackhammers," says chemist James Tour from Rice University. "They are more than one million times faster in their mechanical motion than the former Feringa-type motors, and they can be activated with near-infrared light rather than visible light."

In tests on cultured, lab-grown cancer cells, the molecular jackhammer method scored a 99 percent hit rate at destroying the cells. The approach was also tested on mice with melanoma tumors, and half the animals became cancer-free. The structure and chemical properties of aminocyanine molecules mean they stay in sync with the right stimulus -- such as near-infrared light. When in motion, the electrons inside the molecules form what's known as plasmons, collectively vibrating entities that drive movement across the whole of the molecule. The plasmons have an arm on one side, helping to connect the molecules to the cancer cell membranes while the movements of the vibrations bash them apart. It's still early days for the research, but these initial findings are very promising. The research has been published in Nature Chemistry.

AstroForge, a private company, wants to mine a space rock, but it doesn't want the competition to find out which one. From a report: For generations, Western space missions have largely occurred out in the open. We knew where they were going, why they were going there and what they planned to do. But the world is on the verge of a new era in which private interests override such openness, with big money potentially on the line. Sometime in the coming year, a spacecraft from AstroForge, an American asteroid-mining firm, may be launched on a mission to a rocky object near Earth's orbit. If successful, it will be the first wholly commercial deep-space mission beyond the moon. AstroForge, however, is keeping its target asteroid secret.

The secret space-rock mission is the latest in an emerging trend that astronomers and other experts do not welcome: commercial space missions conducted covertly. Such missions highlight gaps in the regulation of spaceflight as well as concerns about whether exploring the cosmos will continue to benefit all humankind. "I'm very much not in favor of having stuff swirling around the inner solar system without anyone knowing where it is," said Jonathan McDowell, an astronomer at the Harvard-Smithsonian Center for Astrophysics in Massachusetts. "It seems like a bad precedent to set." But for AstroForge, the calculation is simple: If it reveals the destination, a competitor may grab the asteroid's valuable metals for itself. "Announcing which asteroid we are targeting opens up risk that another entity could seize that asteroid," said Matt Gialich, AstroForge's chief executive.

From the depths of the Amazon rainforest to the deserts of Antarctica, huge questions remain unanswered about life on Earth. The Guardian asked leading scientists and conservationists: what is the one thing you would like to know about the planet that remains a mystery? TLDR, the questions/wishes are:1. How many species are there on Earth?
2. I'd go back 540m years to see the 'biological big bang'
3. Could some of the smallest life forms help avert climate crisis?
4. What is the full biodiversity of the Amazon or Congo basin rainforests?
5. How do animals influence the functioning of Earth?
6. What will happen to the Gulf Stream?
7. Do universal rules govern how plants and animals evolve?
8. How many humans could Earth support?
9. Which species will adapt to the climate crisis -- and which will not?

Abstract of a paper published on the American Psychological Association: People are frequently invited to join others for fun social activities. They may be invited to lunch, to attend a sporting event, to watch the season finale of a television show, and so forth. Invitees -- those who are on the receiving ends of invitations -- sometimes accept invitations from inviters -- those who extend invitations -- but other times, invitees decline. Unfortunately, saying no can be hard, leading invitees to accept invitations when they would rather not. The present work sheds light on one factor that makes it so hard to decline invitations.

We demonstrate that invitees overestimate the negative ramifications that arise in the eyes of inviters following an invitation decline. Invitees have exaggerated concerns about how much the decline will anger the inviter, signal that the invitee does not care about the inviter, make the inviter unlikely to offer another invitation in the future, and so forth. We also demonstrate that this asymmetry emerges in part because invitees exaggerate the degree to which inviters focus on the decline itself, as opposed to the thoughts ran through the invitee's head before deciding. Indeed, across multiple studies, we find support for this process through mediation and moderation, while simultaneously finding evidence against multiple alternative accounts. We conclude with a discussion of the contributions and limitations of this research, along with directions for future work.

"It's like visiting an old friend for the holidays," according to this article: Approaching his 86th birthday, Donald Knuth — Stanford's beloved computer science guru — honored what's become a long-standing tradition. He gave a December "Christmas lecture" that's also streamed online for all of his fans...

More than 60 years ago, back in 1962, a 24-year-old Donald Knuth first started writing The Art of Computer Programming — a comprehensive analysis of algorithms which, here in 2023, he's still trying to finish. And 30 years ago Knuth also began making rare live appearances each December in front of audiences of Stanford students...

Recently Stanford uploaded several decades of Knuth's past Christmas lectures, along with a series of 22 videos of Knuth from 1985 titled "the 'Aha' Sessions'" (courses in mathematical problem-solving). There are also two different sets of five videos from 1981 showing Knuth introducing his newly-created typesetting system TeX. There are even 12 videos from 1982 of what Knuth calls "an intensive course about the internal details."

And on Dec. 6, wearing his traditional brown holiday sweater, Knuth gave yet another live demonstration of the beautifully clear precision that's made him famous.

"The age of the dinosaurs ended 66 million years ago when a city-size asteroid struck a shallow sea off the coast of what is now Mexico," writes CNN.

"But exactly how the mass extinction of 75% of the species on Earth unfolded in the years that followed the cataclysmic impact has remained unclear." Previous research suggested that sulfur released during the impact, which left the 112-mile-wide (180-kilometer-wide) Chicxulub crater, and soot from wildfires triggered a global winter, and temperatures plunged. However, a new study published Monday in the journal Nature Geoscience suggests that fine dust made from pulverized rock thrown up into Earth's atmosphere in the wake of the impact likely played a greater role. This dust blocked the sun to an extent that plants were unable to photosynthesize, a biological process critical for life, for almost two years afterward.

"Photosynthesis shutting down for almost two years after impact caused severe challenges (for life)," said lead study author and planetary scientist Cem Berk Senel, a postdoctoral researcher at the Royal Observatory of Belgium. "It collapsed the food web, creating a chain reaction of extinctions."

To reach their findings, scientists developed a new computer model to simulate the global climate after the asteroid strike. The model was based on published information on Earth's climate at that point in time, as well as new data from sediment samples taken from the Tanis fossil site in North Dakota that captured a 20-year period during the aftermath of the strike.

Slashdot reader sciencehabit writes: If you've ever seen a cow staring vacantly across a field, or a pig rolling around in its own filth, you might not think there's a lot going on in their head. You wouldn't be alone. People haven't given much credence to the intelligence of farm animals, and neither have scientists. But that's starting to change.

A growing field of research is showing that—when it comes to the minds of goats, cows, and other livestock—we may have been missing something big. Studies published over the past few years have shown that pigs show signs of empathy, goats rival dogs in some tests of social intelligence, and cows can be potty trained.

Much of this work is being carried out at the Research Institute for Farm Animal Biology (FBN) in Dummerstorf, Germany, one of the world's leading centers for investigating the minds of creatures that often end up on our dinner plate. From cows making friends to goats exhibiting signs of altruism, farm animals are upending popular—and scientific—conceptions of what's going on in their minds.

The work may not just rewrite our thinking about livestock, it might also change how we treat them. As Jan Langbein, an applied ethologist at FBN told says, 'If we don't understand how these animals think, then we won't understand what they need. And if we don't understand what they need, we can't design better environments for them.'

The New Yorker looks at 41-year-old Amabel Holland, an autistic board-game designer who "thinks about the world in terms of systems," and realized you could make a board game about almost anything, "and, when you did, its rules could both mirror and analyze the subject on which it was based."

They've since designed more than 60 games, and the article notes that Holland's work, "which is part of a larger turn toward complexity in the industry, often tackles historical and social subjects — death, religion, misinformation — using surprising 'mechanics,' or building blocks of game play, to immerse players in an experience." "With every game, you build a certain model of the world," Reiner Knizia, a former mathematician who's designed more than eight hundred games, told me. Several of his games illustrate market forces: in Modern Art, for instance, you play as auctioneers and buyers, hoping to buy low and sell high. Knizia is a traditional game designer inasmuch as he aims to "bring enjoyment to the people." But Amabel sometimes aims for the opposite of enjoyment... This Guilty Land, from 2018, is about the struggle to end slavery."
Holland says their games are "meant to evoke frustration" — specifically to communicate how difficult it can be to actually achieve political progress.

Thanks to Slashdot reader silverjacket for sharing the article.

Scientists have developed a vibrating pill that, when swallowed before eating, can create a feeling of fullness. The Guardian reports: The research, which has yet to be carried out in humans, shows that after 30 minutes of activity by the Vibes pill, pigs ate on average almost 40% less food in the following half hour than they did without the device, and gained weight more slowly. The Vibes name is an acronym derived from the pill's full title -- Vibrating Ingestible BioElectronic Stimulator. The work in pigs suggests the vibrations activate stretch receptors in the stomach, simulating the presence of food. This results in signals being sent to the hypothalamus in the brain via the vagus nerve, increasing levels of various hormones that give rise to a feeling of fullness and decreasing those that result in feelings of hunger.

"We envision the Vibes pill being ingested on a relatively empty stomach 20 to 30 min before anticipated meals to trigger the desired sensation of satiety early in the meal,â the team write, adding that when produced at scale, the cost of the pills is expected to be in the cents to one dollar range. The vibrations, which are powered by a battery encased in the swallowed capsule, can be triggered when stomach acid dissolves a membrane around the pill, or by a timer. The researchers say the pills, which are about the size of a large vitamin tablet, offer a non-invasive, temporary therapy, without the need for weight-loss surgery, and exit the body with other solid waste -- meaning in humans they are flushed down the toilet. However they suggest it could be possible to develop pills that are implanted, or stay in the stomach, to reduce the need for people to repeatedly take them, should they require continuing therapy. Further reading: Man Reports PillCam Stuck In His Gut For Over 12 Weeks

An anonymous reader quotes a report from The Guardian: From empty glasses of sherry on the mantelpiece to sooty footprints leading to the bedroom door, evidence of Santa's existence is clearly irrefutable. Yet most children will begin to question it at some point -- and many parents anticipate this moment with dread. Now psychologists have identified the average age when Santa skepticism creeps in, and which children are at greatest risk of harboring negative feelings when it does.

While most adults have fallen for the myth that Santa doesn't exist, many children still believe -- even if the idea of a single individual visiting the homes of billions of children in a single night is at odds with their wider reasoning skills. Dr Candice Mills, a psychologist at the University of Texas in Dallas, US, and a Santa sceptic, said: "Children typically begin to distinguish fantasy from reality during the preschool years, but their belief in the existence of a singular magical Santa Claus often continues into middle childhood." [...] To better understand this shift from belief to disbelief and children's experiences of it, Mills and her colleagues interviewed 48 six- to 15-year-olds who had stopped believing in Santa and 44 of their parents, plus a further 383 adults.

The research, which has not yet been peer reviewed, found that for most children, disbelief crept in gradually about the age of eight -- although some three- or four-year-olds had convinced themselves that Santa wasn't real, while other children believed in him until they were 15 or 16. In many cases, it was testimony from other disbelievers that finally crushed their faith. Mills said: "They may have had some skepticism based on logical reasoning -- like how can Santa Claus really get around the world in one night? -- but what pushes them over the edge is a classmate at school saying he's not real."

An anonymous reader shares a report: It may be the season of loving and giving, but doctors have warned against embracing this spirit too enthusiastically -- at least where sexual relations are concerned. They have discovered that the Christmas period is associated with a significantly increased risk of penile fractures -- a medical emergency in which the erection-producing regions of the penis snap, usually as a result of forceful bending during over-enthusiastic sexual intercourse. "This injury tends to occur during wild sex -- particularly in positions where you're not in direct eye contact [with your partner], such as the reverse cowgirl," said Dr Nikolaos Pyrgides, a urologist at the Ludwig Maximilian University of Munich, who led the research.

The fractures are often heralded by an audible crack, followed by severe pain, rapid loss of erection and severe swelling and bruising. "When [patients] present to their doctor their penis often looks like an eggplant," Pyrgides said. Suspecting that the intimacy and euphoria of the festive season might be a risk factor for this type of injury, Pyrgides and his colleagues examined hospital data for 3,421 men who sustained penile fractures in Germany between 2005 and 2021. The study -- the first to explore seasonal patterns for this type of injury -- found that such injuries were indeed more common over Christmas. In fact, "if every day was like Christmas, 43% more penile fractures would have occurred in Germany from 2005 on," Pyrgides said. The research, which was published in the British Journal of Urology International, also found the risk increased at weekends and over the summer holidays. However, New Year's Eve was not associated with an increased incidence of penis injuries.

In 2005, the reclassification of pseudoephedrine to behind-the-counter status led to widespread use of oral phenylephrine in OTC decongestants, despite evidence of its ineffectiveness. Randy Hatton, a clinical professor in the College of Pharmacy at the University of Florida, and his colleague worked to bring this issue to the FDA's attention, revealing loopholes in the regulatory process for older OTC drugs. Hatton writes in an opinion piece for Scientific American: Before the FDA required that drugs had to be proven effective, it determined whether OTC drugs were effective through expert panels that reviewed existing data. These OTC monographs establish what older OTC ingredients can be marketed without FDA approval. The oral decongestant monograph panel reviewed a few published studies and multiple unpublished studies for phenylephrine. Of the unpublished studies, only four studies showed oral phenylephrine was effective, while seven showed it was no better than placebo. We requested copies of all evidence used by the nasal decongestant review panel via a Freedom of Information Act request and performed a systematic review and meta-analysis ourselves. [...]

The FDA has multiple regulatory processes for different types of medicinal compounds. People are perhaps most familiar with the New Drug Application process, which leads to clinical trials for prescription drug approvals. However, many OTC or nonprescription drugs are regulated differently. In fact, a law passed in 1951, the Durham-Humphrey Amendment to the 1938 Food, Drug, and Cosmetic Act, created the categories of prescription and nonprescription drugs. In 1962, the act was amended again so that drugs had to be shown to be effective, hence the requirement for well-done clinical trials. But what about the drugs that were approved before 1962? This is the loophole that some OTC drugs fall through. For prescription drugs, FDA tried to address pre-1962 approvals through a review of over 3,000 prescription drugs. Most of those drugs have now been reviewed and addressed, but there are still unapproved prescription drugs on the market today, such as an extended-release form of oral nitroglycerin. For nonprescription drugs, FDA established the OTC monograph process 10 years after the 1962 amendment to the Food, Drug, and Cosmetic Act, which required products not proven effective to be reconsidered. FDA formed advisory panels grouping hundreds of ingredients into 26 categories based on the products' uses. After gathering all available information, both published and unpublished, from manufacturers, the advisory panels issued final reports to FDA about whether these ingredients were GRASE (generally recognized as safe and effective), not GRASE, or inconclusive. GRASE ingredients can be used in nonprescription drugs without FDA approval if the use matches the monograph. "The oral phenylephrine example shows that FDA needs more funding to look at these old drugs," concludes Hatton. "We need public funds to support independent researchers who want to examine these products objectively. The government should be able to spend millions to save consumers billions on ineffective products. Companies that market these products have no incentive to prove they don't work. Nonprescription drugs must be effective -- not just safe."

During a meeting of the National Space Council, Vice President Kamala Harris said an international astronaut will land on the Moon during one of NASA's Artemis missions. "Today, in recognition of the essential role that our allies and partners play in the Artemis program, I am proud to announce that alongside American astronauts, we intend to land an international astronaut on the surface of the Moon by the end of the decade," Harris said. Ars Technica reports: Although the National Space Council is useful in aggregating disparate interests across the US government to help form more cohesive space policies, public meetings like the one Wednesday can seem perfunctory. Harris departed the stage soon after her speech, and other government officials read from prepared remarks during the rest of the event. Nevertheless, Harris' announcement highlighted the role the space program plays in elevating the soft power of the United States. It was widely assumed an international astronaut would eventually land on the Moon with NASA. Harris put a deadline on achieving this goal.

NASA has long included astronauts from its international partners on human spaceflight missions, dating back to the ninth flight of the space shuttle in 1983, when West German astronaut Ulf Merbold joined five Americans on a flight to low-Earth orbit. This was seen by US government officials as a way to foster closer relations with like-minded countries. The inclusion of foreign astronauts on US missions also repays partner nations who make financial commitments to US-led space projects with a high-profile flight opportunity for one of their citizens.

Among the international partners contributing to Artemis, it seems most likely a European astronaut would get the first slot for a landing with NASA. ESA funded the development of the service modules used on NASA's Orion spacecraft, which will ferry astronauts from Earth to the Moon and back. These modules provide power and propulsion for Orion. ESA is also developing refueling and communications infrastructure for the Gateway mini-space station to be constructed in orbit around the Moon.

A Japanese astronaut might also have a shot at getting a seat on an Artemis landing. Japan's government has committed to providing the life-support system for the Gateway's international habitation module, along with resupply services to deliver cargo to Gateway. Japan is also interested in building a pressurized rover for astronauts to drive across the lunar surface. In recognition of Japan's contributions, NASA last year committed to flying a Japanese astronaut aboard Gateway. Canada is building a robotic arm for Gateway, but a Canadian astronaut already has a seat on NASA's first crewed Artemis mission, albeit without a trip to the lunar surface.

An anonymous reader quotes a report from the Los Angeles Times: It was the late 1980s when Gary Mund felt his pinky tremble. At first it seemed like a random occurrence, but pretty quickly he realized something was seriously wrong. Within two years, Mund -- a crew worker with the Eastern Municipal Water District in Riverside County -- was diagnosed with Parkinson's disease. The illness would eventually consume much of his life, clouding his speech, zapping most of his motor skills and taking away his ability to work and drive. "It sucks," said Mund, 69. He speaks tersely, because every word is a hard-won battle. "I was told the herbicide wouldn't hurt you."

The herbicide is paraquat, an extremely powerful weed killer that Mund sprayed on vegetation as part of his job from about 1980 to 1985. Mund contends the product is responsible for his disease, but the manufacturer denies there is a causal link between the chemical and Parkinson's. Paraquat is manufactured by Syngenta, a Swiss-based company owned by the Chinese government. The chemical is banned in at least 58 countries -- including China and Switzerland -- due to its toxicity, yet it continues to be a popular herbicide in California and other parts of the United States. But research suggests the chemical may cross the blood-brain barrier in a manner that triggers Parkinson's disease, a progressive, neurodegenerative disorder that affects movement. Now, Mund is among thousands of workers suing Syngenta seeking damages and hoping to see the chemical banned.

Since 2017, more than 3,600 lawsuits have been filed in state and federal courts seeking damages from exposure to paraquat products, according to Syngenta's 2022 financial report (PDF). [...] Paraquat is 28 times more toxic than another controversial herbicide, Roundup, according to a report from the Pesticide Action Network. (Roundup has been banned in several parts of California, including a 2019 moratorium by the Los Angeles County Board of Supervisors forbidding its use by county departments.) Paraquat also has other known health effects. It is listed as "highly toxic" on the U.S. Environmental Protection Agency's website, which says that "one small sip can be fatal and there is no antidote." The EPA is currently reviewing paraquat's approval status. However, both the EPA and Syngenta cited a 2020 U.S. government Agricultural Health Study that found there is no clear link between paraquat exposure and Parkinson's disease. A 2021 review of reviews similarly found that there is no causal relationship.